Your browser is out-of-date!

Update your browser to view this website correctly.

1Cookies

2Disclaimer

Current market commentary with Dr. Daniel Koller, Head Investment Management Team BB Biotech at Bellevue Asset Management.

BB Biotech: «Cancer medicine improves the chances of a cure»

Current market commentary with Dr. Daniel Koller, Head Investment Management Team BB Biotech at Bellevue Asset Management.
09.12.2021 - Daniel Koller

These investment strategies might interest you

  • BB Biotech AG

    BB Biotech AG (SIX) (CHF)
    ISIN-No.: CH0038389992YTD: 26.76%Active share: 79.47Anzahl Positionen: 22
    Launch date: 16. November 1993